| Document |
Document Title |
|
WO/2024/097897A1 |
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
|
|
WO/2024/094156A1 |
Provided is a compound represented by formula (I), or a stereoisomer thereof, an optical isomer thereof, a solvate thereof, an isotope derivative thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a ligan...
|
|
WO/2024/092864A1 |
A magnolol/glycosyl furan double-bio-based epoxy resin monomer, a preparation method therefor and a use thereof. The magnolol/glycosyl furan double-bio-based epoxy resin monomer is as shown in formula MF. A polymer material has a high gl...
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/088928A1 |
The invention relates to novel processes for manufacturing 6-[[5-methyl-3-(6-methyl-3- pyridyl)isoxazol-4-yl]methoxy]-N-tetrahydropyran-4-yl-pyrida
zine-3-carboxamide (1), or a pharmaceutically acceptable salt thereof. The processes acco...
|
|
WO/2024/088296A1 |
The present disclosure relates to a piperidinopyrimidine derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a piperidinopyrimidine derivative as represented by gener...
|
|
WO/2024/085354A1 |
The present invention provides, in the present specification, a heterocyclic compound and an organic light-emitting device including same.
|
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
|
WO/2024/070902A1 |
Provided is a compound represented by formula (1). (In the formula, R1 represents a hydrogen atom or a methyl group; R2 represents an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an aryl group whi...
|
|
WO/2024/073129A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
|
WO/2024/072108A1 |
The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscop...
|
|
WO/2024/066916A1 |
Disclosed are an aromatic amine compound comprising a quaterphenyl structure and an organic electroluminescent device comprising the same. The aromatic amine compound has a structure represented by formula (I). The compound has the follo...
|
|
WO/2024/072109A1 |
The present invention relates to a co-crystal of enavogliflozin. The enavogliflozin co-crystal of the present invention increased the solubility of enavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improvem...
|
|
WO/2024/073502A1 |
The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
|
|
WO/2024/071143A1 |
The present invention provides a photoelectric conversion element that exhibits excellent quantum efficiency when having received blue light. Also provided are an imaging element, a light sensor, a compound, and a compound production met...
|
|
WO/2024/064245A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases media...
|
|
WO/2024/062310A1 |
The present invention provides derivatives of (2S,3R,4R,5S,6R)-2-[4- chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]-phenyl]-6-(
hydroxymethyl)- oxan-3,4,5-triol (empagliflozin) and (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl...
|
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2024/056096A1 |
The present invention relates to a crystal form of a nitrogen-containing heterocyclic ketone compound and a preparation method therefor. Specifically, the present invention relates to a salt having a compound represented by general formu...
|
|
WO/2024/051700A1 |
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically disclosed is a compound having a structure as represented by formula (I) as a GLP1R agonist, or a pharmaceu...
|
|
WO/2024/051816A1 |
Provided is a bicyclic PRMT5 inhibitor, which is a compound having a structure represented by formula (I). Further provided are a preparation method for the compound and use of the compound in regulating PRMT5 activity or treating PRMT5-...
|
|
WO/2024/052871A1 |
The object of the invention is a novel ruthenium complex of the general formula Ru-1, in which all the variable substituents have the meanings defined in the description. Also an object of the invention is a method for obtaining the ruth...
|
|
WO/2024/050815A1 |
Provided is the use of heteroaromatic ring compounds in nucleic acid tests. Particularly provided are the use of heteroaromatic ring compounds as a nucleic acid protective agent in nucleic acid tests, a method for inhibiting degradation ...
|
|
WO/2024/049977A1 |
Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are com...
|
|
WO/2024/046409A1 |
The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...
|
|
WO/2024/046253A1 |
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...
|
|
WO/2024/041613A1 |
The present disclosure relates to a heterocyclic compound, a method for preparing same, and pharmaceutical use thereof. Specifically, the present disclosure relates to a heterocyclic compound represented by general formula (I), a method ...
|
|
WO/2024/042146A2 |
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufa...
|
|
WO/2024/035950A1 |
Provided are compounds of the Formula (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
|
|
WO/2024/026568A1 |
Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compound...
|
|
WO/2024/027521A1 |
Provided are a methylophiopogonone A derivative, and the preparation and the use thereof. The present invention specifically relates to three derivatives of methylophiopogonone A, which derivatives have the chemical structures of formula...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/025151A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
|
|
WO/2024/025353A1 |
The present invention relates to: an organic compound employed as an organic layer material, such as an electron-blocking layer in an organic light-emitting device; and an organic light-emitting device comprising same. When the compound ...
|
|
WO/2024/019661A1 |
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...
|
|
WO/2024/014716A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2024/009283A1 |
Angiotensin AT2 receptor antagonists have been clinically validated for the treatment of chronic neuropathic pain. We discovered a series of lead compounds comprising a trisubstituted heterocyclic core that show high in vitro (sub-nanomo...
|
|
WO/2024/009308A1 |
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.
|
|
WO/2024/005431A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2024/005428A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/237732A1 |
The invention concerns compounds having antiviral activity, in particular having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising th...
|
|
WO/2023/235929A1 |
The present disclosure relates generally to compounds with anti-cancer and/or anti-fibrotic properties. In particularn the disclosure relates to functionalised benzopyran compounds, the preparation thereof, and their use.
|
|
WO/2023/239193A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/234603A1 |
The present invention relates to an organic compound employed in an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting device. The organic compound according to the present invention...
|
|
WO/2023/225916A1 |
Disclosed is a method for preparing 4-thioflavone compound from a hydroxychalcone compound and xanthate, wherein the hydroxychalcone compound and the xanthate react in a solvent to prepare a thioflavone compound. In view of the huge appl...
|
|
WO/2023/227695A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/227117A1 |
Provided in the present invention is a 3C-like protease inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof. Also provided in ...
|
|
WO/2023/228790A1 |
The present invention provides a fluorescent-probe solution in which the fluorescent probe is inhibited from decreasing in purity. This fluorescent-probe solution comprises a compound represented by formula (I) or a salt thereof, at leas...
|
|
WO/2023/229228A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device including same.
|
|
WO/2023/224020A1 |
Provided is a compound represented by formula (1). (The symbols in formula (1) are as defined in the specification.) Also provided are an organic electroluminescent element that contains the compound and an electronic device that include...
|
